Tevogen Bio Holdings (TVGN) Change in Accured Expenses (2022 - 2026)
Tevogen Bio Holdings (TVGN) reported Change in Accured Expenses of -$258417.0 for Q1 2026, down 194.09% on a YoY basis from $274650.0 in Q1 2025, and down 168.7% quarter-over-quarter from $376143.0 in Q4 2025.
Tevogen Bio Holdings (TVGN) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings has reported Change in Accured Expenses for 5 years, with the latest figure at -$258417.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 194.09% year-over-year to -$258417.0; the trailing twelve-month figure through Mar 2026 stood at -$607270.0 (down 254.15% YoY), and the FY2025 full-year result was -$74203.0, up 89.11% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$258417.0, down from $376143.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $376143.0 in Q4 2025, with the low at -$800742.0 in Q1 2024.
- Historically, Change in Accured Expenses has averaged -$85107.2 across 5 years, with a median of -$7451.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 656.88% — and 2024, when it plunged 1405.89%.
- Tevogen Bio Holdings' Change in Accured Expenses stood at $38671.0 in 2022, then sank by 474.1% to -$144669.0 in 2023, then soared by 292.66% to $278722.0 in 2024, then jumped by 34.95% to $376143.0 in 2025, then sank by 168.7% to -$258417.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$258417.0 (Q1 2026), $376143.0 (Q4 2025), and -$379140.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Tevogen Bio Holdings | 182.04 Mn | 181.35 Mn | - | -258,417.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -258,417.00 |
| Mar 31, 2026 | -258,417.00 |
| Dec 31, 2025 | 376,143.00 |
| Dec 31, 2025 | 376,143.00 |
| Sep 30, 2025 | -379,140.00 |
| Sep 30, 2025 | -379,140.00 |
| Jun 30, 2025 | -345,856.00 |
| Jun 30, 2025 | -345,856.00 |
| Mar 31, 2025 | 274,650.00 |
| Mar 31, 2025 | 274,650.00 |
| Dec 31, 2024 | 278,722.00 |
| Dec 31, 2024 | 278,722.00 |
| Sep 30, 2024 | -370,643.00 |
| Sep 30, 2024 | -370,643.00 |
| Jun 30, 2024 | 211,213.00 |
| Jun 30, 2024 | 211,213.00 |
| Mar 31, 2024 | -800,742.00 |
| Mar 31, 2024 | -800,742.00 |
| Dec 31, 2023 | -144,669.00 |
| Dec 31, 2023 | -144,669.00 |